In further secondary analyses, we evaluated the comparative effectiveness of MOUD with individual cooccurring SUDs, observing comparable protective associations with buprenorphine treatment days for individuals without cooccurring SUD (OR, 0.57 [95% CI, 0.53-0.63]) and those with alcohol use disorder (OR, 0.57 [95% CI, 0.47-0.69]), stimulant use disorder (OR, 0.78 [0.63-0.96]), and sedative use disorder (OR, 0.79 [95% CI, 0.64-0.98]) (Figure 2). While no association was observed between ER naltrexone and odds of drug-related poisoning for individuals with cooccurring sedative use disorder, comparable results were otherwise observed in all other comparisons (Figure 2). No protective association was observed for oral naltrexone.
